ARTICLE | Clinical News
Vimizim elosulfase alfa regulatory update
December 9, 2013 8:00 AM UTC
BioMarin submitted an NDS for Priority Review to Health Canada for Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). Priority Review allows for a shortened revi...